As the Darwinian view ascends, the future of pharmacokinetics lies not in defending old paradigms, but in forging new ones grounded in the irreducible diversity of life.
Peptides stand at the frontier of drug development, poised to exploit their unique blend of specificity and adaptability.
The synthesis of neutron scattering, lipidomics, and photochemical analyses redefines PSI as a lipid-protein supercomplex, where every molecular component is a deliberate player in the photosynthetic symphony.
MOSES serves as both compass and crucible, guiding researchers through chemical space while rigorously testing their innovations.
The rise of biocatalysis and flow chemistry demands periodic updates to fragment libraries and complexity metrics.
AI algorithms now design molecules from scratch, optimizing pharmacological profiles through iterative learning.
AI-driven de novo protein design is transforming the way scientists approach molecular engineering.
Polaritonic chemistry steers, inhibits, and catalyzes chemical processes at room temperature, controlled by parameters like cavity mirror spacing.
The encapsulation of norfloxacin in PEBSA-based microparticles marks a transformative development in antibiotic delivery.
Targeting osteopontin could redefine the landscape of cancer therapy, transforming resistance into a treatable challenge.
Histidine-lysine (HK) peptides could transform siRNA therapeutics, enabling personalized cancer care and tackling untreatable conditions.
By targeting ferroptosis, apoptosis, and autophagy while modulating MYC, TG1 disrupts the intricate survival networks of CRC cells.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings